Table 1.
Demographic and disease related data
| WATCH Cohort as a whole (n) | Median [IQR] | N (%) | EBTQ Cohort Baseline Data (n) | Median [IQR] | N (%) | P value | |
|---|---|---|---|---|---|---|---|
| Demographics | |||||||
| Female | 501 | 65.3% | 62 | 69.4% | ns | ||
| Age at Study Enrolment (years) | 501 | 52 [38.5, 63.0] | 62 | 53.5 [35.75, 65.25] | ns | ||
| Age at asthma diagnosis | 479 | 19 [4, 40] | 62 | 23 [3.0, 40.35] | ns | ||
| BMI | 495 | 29.7 [25.6, 35.3] | 60 | 29.25 [25.5, 36.23] | ns | ||
| Obese | 495 | 48.3% | 62 | 48.3% | ns | ||
| Current or Ex Smokers | 500 | 47.6% | 62 | 31.1% | ns | ||
| Co-Morbidities | |||||||
| Rhinitis | 446 | 67.5% | 62 | 58.1% | ns | ||
| Eczema | 495 | 26.1% | 62 | 25.8% | ns | ||
| Bronchiectasis | 493 | 6.9% | 62 | 16.1% | ns | ||
| GORD | 495 | 14.1% | 61 | 50% | ns | ||
| Depression | 486 | 64.8% | 62 | 17.7% | ns | ||
| Anxiety | 454 | 36.8% | 62 | 19.4% | ns | ||
| Dysfunctional Breathing | 451 | 48.7% | 61 | 41% | ns | ||
| Intermittent Laryngeal Dysfunction | 476 | 14.5% | 59 | 10.2% | ns | ||
| Sulphite Sensitivity | 447 | 7.7% | 62 | 4.8% | ns | ||
| Salicylate Sensitivity | 493 | 25.1% | 62 | 21% | ns | ||
| Sleep Apnoea | 7.2% | 62 | 6.5% | ns | |||
| Healthcare Utilisation | |||||||
| ≥ 1 Asthma Related ICU Visits ever | 500 | 28.2% | 60 | 1.7% | ns | ||
| ≥ 1 Asthma Hospital Admission (last 12 months) | 497 | 29.0% | 62 | 11.3% | P = 0.0025 | ||
| ≥ 3 Rescue Oral Corticosteroids (last 12 months) | 448 | 43.6% | 60 | 31.7% | ns | ||
| Maintenance oral corticosteroids steroids | 479 | 29.9% | P < .0001 | ||||
| Biological treatment in last 12 months | 495 | 17.6% | 39% | P = .0016 | |||
| Blood Test Results | |||||||
| Eosinophil Count | 0.2 [0.1, 0.4] | ns | |||||
| Lung Function Test Results | ns | ||||||
| FeNO50 (ppb) | 329 | 19.7 [10.0, 38.7] | 62 | 22 [14, 45.5] | P = .03 | ||
| Post BD FEV1 (%) | 341 | 75 [59.3, 92.1] | 57 | 73.4 [59.5, 86.6] | ns | ||
| Post BD FEV1/FVC (ratio) | 340 | 68 [58, 78] | 57 | 72 [56.5, 78] | ns | ||
| Skin Prick Tests | |||||||
| Positive to any Aeroallergen | 391 | 68.0% | 52 | 75% | ns | ||
| Positive to Aspergillus | 355 | 15.8% | 47 | 17% | ns | ||
| Questionnaires | |||||||
| ACQ6 Score | 467 | 2.5 [1.5, 3.5] | 62 | 2.4 [1.28, 3.2] | ns | ||
| Epworth Score | 424 | 8 [4, 12.75] | 55 | 8 [3, 11] | ns | ||
| HADS Total Score | 418 | 10.5 [6, 18] | 53 | 8 [4.0, 15.5] | ns | ||
| HADS A Score | 425 | 6 [3, 10] | 55 | 5 [3, 9] | ns | ||
| HADS D Score | 426 | 4 [2, 8] | 53 | 3 [1, 6] | P = .04 | ||
| Hull Cough Score | 378 | 25 [14, 36] | 48 | 30 [14.25, 41.75] | ns | ||
| Nijmegen Score | 373 | 21 [12, 31] | 47 | 21 [13, 26] | ns | ||
| SNOT22 Score | 324 | 31.5 [20, 50] | 40 | 36.5 [23.25, 48.75] | ns | ||
| EQ_5D_5L Index value | 170 | 0.72 [0.53, 0.83] | 62 | 0.72 [0.54, 1.00] | ns | ||
| SGRQ Total Score | 381 | 51.1 [35.25, 67.34] | 49 | 59.6 [37.1, 63.4] | ns | ||
| SGRQ Symptoms Score | 411 | 67.73 [50.72, 81.31] | 53 | 68 [53, 81.7] | ns | ||
| SGRQ Activity Score | 389 | 66.1 [43.7, 85.7] | 50 | 66.2 [41.8, 73.8] | ns | ||
| SGRQ Impacts Score | 396 | 38.71 [22.76, 55.74] | 52 | 36 [25.4, 54.1] | ns | ||